Skip to main content
Bal Pharma Ltd. logo

Bal Pharma Ltd. — Investor Relations & Filings

Ticker · BALPHARMA ISIN · INE083D01012 LEI · 254900F3KMK38GUDIW74 BSE.NS Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2026-05-27 Audit Report / Informat…
Country IN India
Listing BSE.NS BALPHARMA

About Bal Pharma Ltd.

https://www.balpharma.com/

Bal Pharma Ltd. specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations. The organization operates manufacturing facilities compliant with international quality standards, including WHO-GMP certifications. Its product portfolio encompasses a wide range of therapeutic segments, including diabetology, cardiology, gastroenterology, oncology, and pain management. Notable APIs in its catalog include Gliclazide, Ebastine, and Benzydamine. The company maintains an integrated business model, supporting operations from research and development to large-scale production. Bal Pharma serves a global clientele, exporting its products to numerous international markets across multiple continents, while focusing on the delivery of high-quality medicinal products and specialized formulations.

Recent filings

Filing Released Lang Actions
Dividend
Audit Report / Information Classification · 85% confidence The document is a composite regulatory filing containing (1) the outcome of a Board meeting under SEBI LODR (approval of audited financial results, dividend recommendation, senior management appointment, etc.); (2) a declaration of unmodified opinion by statutory auditors; and (3) the full Independent Auditor’s Report on the audited standalone (and consolidated) financial results for the quarter and year ended March 31, 2026, including detailed financial statements. Although it includes board-level disclosures and the actual financial tables, its core feature is the standalone audit report on financial results (Regulation 33) rather than a full annual report or mere announcement. This aligns with our “Audit Report / Information” category (AR). FY 2026
2026-05-27 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is not a full Annual Report (10-K) – it consists of SEBI LODR board meeting outcome disclosures, an unmodified auditor’s opinion under Reg 33, the Independent Auditor’s Report on the quarterly and year‐end results, and then the actual audited standalone financial results for the quarter and year ended March 31, 2026. It therefore contains substantive financial statements for a period shorter than a full fiscal year (quarter end Q4 plus year‐end) and is not simply an announcement or certification. This fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-27 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is a public filing under SEBI LODR. It begins with the ‘Outcome of the Board Meeting’ (Reg 29 intimation) but goes on to enclose and publish the full audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, together with the Independent Auditor’s Report and detailed line‐by‐line financial statements. It is not merely an announcement that a report has been published (RPA/RNS), nor is it a full annual report (10-K), nor solely an audit report (AR). It contains substantive interim/quarterly financial data, meeting the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-27 English
Audited financial results of the company for the quarter and financial year ended 31.03.2026.
Audit Report / Information Classification · 85% confidence The document is a combination of (i) board meeting outcome (Regulation 29 intimation) and declaration of audit opinion under Regulation 33 of SEBI LODR; (ii) the full Independent Auditor’s Report on the quarterly and annual standalone financial results; and (iii) the detailed audited financial results for the quarter and year ended 31.03.2026. This is not a full annual report (10-K) nor a simple earnings release or publication notice, but a standalone audit report and accompanying audited results. Therefore, it falls under the Audit Report/Information category. FY 2026
2026-05-27 English
Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recomme
Interim / Quarterly Report Classification · 85% confidence The document comprises the Board meeting outcome that approves and records the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, includes the auditor’s unmodified opinion, full auditor’s report and the detailed financial tables. It goes well beyond a brief earnings summary (ER) and is not a full-form annual report (10-K), but rather a comprehensive financial report for a quarterly and year-end period filed under SEBI LODR. Therefore it best fits the Interim / Quarterly Report category. FY 2026
2026-05-27 English
Corrigendum
Board/Management Information Classification · 88% confidence The document is an addendum to a previously filed notice of a Board of Directors meeting under SEBI Listing Regulations, specifying additional agenda items (fund raising through preferential issue warrants). This pertains to changes in the company’s board meeting agenda (management/board information). It is not a full report, earnings release, or financial statement, but rather a management announcement regarding board meetings. Therefore, it falls under Board/Management Information (MANG).
2026-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.